DONOSTIA / SAN SEBASTIÁN, Spain, Oct. 19, 2026 /PRNewswire/ -- Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) gene therapy manufacturing, a subsidiary of AskBio, Inc. within the Bayer Group, today announced that Chief Executive Officer (CEO) Jimmy Vanhove will transition to a new role leading the development and expansion of Bayer's U.S. Pharmaceutical Product Supply Network based in New Albany, Ohio. In his new position, Jimmy will join the Pharmaceuticals Division's Product Supply Leadership Team. Angela Ochoa Chico has been appointed as his successor and will join Viralgen as CEO, from her current role at Bayer, effective January 1, 2027. She is an accomplished executive with extensive international leadership experience in pharmaceutical manufacturing and operations.

During Jimmy's four years leading the company, Viralgen has evolved from an emerging contract development and manufacturing organization (CDMO) into a market-leading AAV-specialist CDMO, supporting gene therapy programs from early development through commercial-scale manufacturing. Over this period, the company expanded its facilities, infrastructure, and process development capabilities, becoming a fully integrated, end-to-end CDMO with a strong portfolio of more than 70 customers and partners worldwide.

This progress has been driven by a strong quality mindset, operational reliability, and continuous improvement, with sustainability integrated into Viralgen's growth. Throughout, the company has remained focused on its purpose: bringing life-changing gene therapies closer to patients. From supporting gene therapy manufacturing for market-leading global pharmaceutical companies to more than 15 ultra-rare disease foundations, Viralgen remains committed to people living with rare diseases and the families who support them.

Today, Viralgen employs more than 450 professionals in San Sebastián, Spain, and operates one of the world's largest facilities dedicated to manufacturing AAV-based gene therapies, with integrated capabilities spanning process development, clinical and commercial production, quality control, and fill-finish.

"It has been a privilege to lead Viralgen through this transformative period," said Jimmy Vanhove. "I am especially proud that, as Viralgen has grown, we have remained committed to people living with both common and rare diseases, as well as the patient foundations that represent them. I am confident that Angela will build on this legacy and lead Viralgen into its next exciting chapter."

Angela Ochoa Chico brings nearly twenty years of international experience across pharmaceutical operations, quality, manufacturing, strategy, and organizational transformation. She comes to Viralgen from her role as Product Supply Strategy & Excellence Lead at the Pharmaceuticals Division of Bayer where she has helped shape global manufacturing strategy, strengthen organizational capabilities and drive performance across the Product Supply network. Earlier in her career, she led manufacturing and quality organizations in Mexico and held global roles spanning operations, regulatory affairs, supply chain, and strategic network management.

"I am delighted to join Viralgen at such an important stage in its evolution," said Angela Ochoa Chico. "Viralgen has built an outstanding reputation for scientific excellence, quality, and innovation, supported by an exceptionally talented team. I look forward to building on these strong foundations, advancing our manufacturing capabilities, and further strengthening Viralgen's position as a trusted gene therapy manufacturing partner, guided by a clear purpose to help bring transformative therapies to the patients who need them. Over the coming months, I will work closely with Jimmy and the Viralgen team to ensure a smooth transition into the CEO role."

About Viralgen

Viralgen is a leading Contract Development and Manufacturing Organization (CDMO) specializing exclusively in adeno-associated virus (AAV)-based cell and gene therapies. Founded in 2017 as a subsidiary of AskBio, Inc. within the Bayer AG group, Viralgen delivers end-to-end support from early development to large-scale commercial manufacturing. Leveraging their proprietary Pro10™ suspension cell line and Aava™ manufacturing platform, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes. Located in San Sebastian, Spain, its state-of-the-art facility features three cGMP suites with 2,000-liter capacities each, certified by the AEMPS and integrates services including plasmid production, process optimization, fill-finish, and in-house QC testing. With over 2,000 AAV batches produced, Viralgen provides reliable, efficient solutions to bringing life-changing gene therapies to patients with greater speed and consistency.  Learn more at viralgen.com and follow us on LinkedIn.

Share this article

FAIRFAX, Va., Oct. 19, 2026 /PRNewswire/ -- Allergy & Asthma Network will host the 12th annual USAsthma Summit, a free, one‑day event bringing together the nation's leading voices in asthma care, research, policy and lived experience. The Summit will take place Nov. 13, 2026, in Phoenix, Arizona, and via an interactive livestream, providing broad access to public health professionals, clinicians, asthma educators, respiratory therapists, patients, caregivers, advocates and community partners nationwide.

As asthma continues to affect millions of people in the United States and policymakers consider changes that could impact access to care, the USAsthma Summit provides a national forum to address emerging challenges and identify solutions. Through scientific and medical updates, policy discussions, practical strategies and patient perspectives, attendees will gain insights to help improve asthma care and outcomes in their communities.

The USAsthma Summit coincides with the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, creating opportunities for additional engagement among attendees, speakers and leaders in allergy, asthma and immunology.

Speakers and Sessions

The 2026 program features leaders across medicine, public and environmental health, behavioral health, patient advocacy and lived experience.

- The Asthma Landscape in the United States, Cherie Zachary, MD, FACAAI, President, President of the American College of Allergy, Asthma & Immunology (ACAAI)

- Creating Asthma-Friendly Environments: Action, Innovation and Leadership, Matthew Hiester, Environmental Protection Agency (EPA)

- Integrating Evidence-Based Behavioral Health into Asthma Care, Amanda Whitehouse, PhD

- Bridging Medicine, Research and Community: The Community Health Worker as a Healthcare Provider & Research Extender in Asthma Care, Floribella Redondo-Martinez, CCHW, BS

- SA Kids BREATHE: An Advocacy and Public Health Intervention, Mandie Svatek, MD

- The Great Digital Debate: How AI and Social Media Shape Asthma Care, Payel Gupta, MD and Michael Blaiss, MD

- Federal Mandates, Local Realities: Strategic Priorities to Advance Asthma Care Delivery in the 120th Congress, Miriam O'Day, Payel Gupta, MD and Ashley Strozier

- Patients at the Center of Asthma Care: Real Stories, Real Perspectives, Ashley Strozier, Clarissa Ruffin and Richard Redondo

Who Should Attend?

Allergy & Asthma Network's USAsthma Summit welcomes anyone committed to improving asthma outcomes, including community health workers, public health professionals, asthma coalition members, clinicians across specialties, advocates, people living with asthma and caregivers.

"The USAsthma Summit brings together diverse voices from across the asthma community to share ideas, address challenges and identify solutions," said Lynda Mitchell, CEO of Allergy & Asthma Network. "This year's program highlights emerging science, policy developments, patient perspectives and practical strategies that will help improve care and outcomes for people with asthma."

Registration is free for both in-person and virtual attendees.

To register: https://allergyasthmanetwork.formstack.com/forms/usasthmasummit2026

For full event details: https://allergyasthmanetwork.org/news/usasthma-summit-2026/

For Media

Members of the media are encouraged to arrange interviews with speakers and Allergy & Asthma Network leadership before the Summit. Journalists interested in on-site coverage should contact Jennifer Wilson using the information below. Allergy & Asthma Network representatives are available for interviews, background conversations and story development.

Jennifer Wilson | 571-395-8909 | [email protected]

About Allergy & Asthma Network

Founded in 1985, Allergy & Asthma Network is the leading nonprofit outreach, education, advocacy and research organization for people living with asthma, allergies and related conditions. Our mission is simple yet profound: to advance patient-centered research and advocate for better outcomes, access to care, education, and treatments that lead to improved health and quality of life. We specialize in making medically accurate information understandable to all, promoting evidence-based care, and fostering collaboration among patients, clinicians, researchers, advocates and policymakers. Learn more at AllergyAsthmaNetwork.org.

SOURCE Allergy & Asthma Network

Share this article

NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; "Lindblad"; the "Company"), a global provider of expedition cruises and adventure travel experiences, will report 2026 third quarter financial results on Tuesday, November 3, 2026, before the market opens, and will host an audio conference webcast to discuss the results at 9:00 am Eastern Time.

The webcast can be accessed on the Company's website at investors.expeditions.com, or at https://events.q4inc.com/attendee/416185057.

To participate in the Q&A, use the analyst registration to receive a unique passcode, https://events.q4inc.com/analyst/416185057?pwd=BmWfj6ho.

The conference can also be accessed by phone, dial-in numbers by country available at https://help.events.q4inc.com/eahc/international-dial-in-numbers, meeting ID 416185057.

Replays will be available at investors.expeditions.com within 48 hours of its completion.

The earnings release will be available in the investor relations section of the Company's website at investors.expeditions.com.

About Lindblad Expeditions

Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; the "Company") is a leader in global expedition travel, offering immersive, educational journeys that span all seven continents through its eight pioneering brands. Driven by a passion for the planet and the belief that there is always more to be discovered, the Company leads travelers to the farthest reaches of the world with an expansive portfolio of ship- and land-based expeditions. In collaboration with National Geographic, Lindblad Expeditions operates and sells the National Geographic-Lindblad Expeditions co-brand, which offers ship-based voyages that allow guests to explore remote destinations alongside scientists and naturalists, and with state-of-the-art exploration tools. In addition to its renowned modern expedition cruises, the Company's award-winning land-based brands—Natural Habitat Adventures, Off the Beaten Path, DuVine Cycling + Adventure Co., Classic Journeys, Wineland-Thomson Adventures, White Desert and Echo Charlie—provide extraordinary wildlife, cultural, and adventure-focused experiences. Together, these brands connect travelers with some of the planet's most inspiring natural and cultural landscapes, fostering a deep appreciation for the world.

To learn more about Lindblad Expeditions Holdings, Inc., its growing portfolio of brands, and the Company's commitment to responsible exploration, visit investors.expeditions.com.

SOURCE Lindblad Expeditions Holdings, Inc.

Share this article

Jackson to lead organic and inorganic growth initiatives, strategic partnerships and corporate development as the Company advances its life sciences and therapeutics platforms

TORONTO, Oct. 19, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the appointment of Angus Jackson as Managing Director of Corporate Development. In this role, Mr. Jackson will assist in the Company's organic and lead the inorganic growth initiatives, with responsibility for advancing strategic partnerships, evaluating acquisition and investment opportunities, and supporting the Company's long-term commercial and corporate development strategy.

Mr. Jackson brings a multidisciplinary background spanning investment banking, corporate law, business strategy and operating experience in the life sciences sector. Most recently, he served as an investment banker at Outcome Capital, a Boston-based boutique investment bank focused on the healthcare and life sciences industries. At Outcome Capital, he advised companies across pharmaceuticals, pharmaceutical services, medical technology and healthcare services on mergers and acquisitions, capital raising and strategic transactions.

Prior to his investment banking career, Mr. Jackson held corporate development and operating responsibilities at a family-owned contract manufacturing business serving the pharmaceutical and life sciences industries, where he was involved in strategic initiatives and acquisitions. Vector believes his combination of transaction execution experience and direct operating exposure positions him to help the Company pursue growth opportunities across its business and technology platforms.

Mr. Jackson holds a Master of Business Administration from the University of Virginia Darden School of Business, a Juris Doctor from the University of Georgia School of Law, and a Master of Laws (LL.M.) from Duke University School of Law, with a focus on law and entrepreneurship. His academic and professional background combines financial analysis, transaction structuring, corporate strategy, entrepreneurship and legal expertise.

Role and Priorities

In his new role, Mr. Jackson will focus on identifying and executing opportunities to accelerate Vector's growth, including commercial expansion, strategic alliances, business development initiatives and selective mergers and acquisitions. He will also work with Company leadership to evaluate opportunities that complement Vector's existing capabilities and support the development and commercialization of its therapeutic delivery technologies, medical devices and peptide-related offerings.

"Disciplined corporate development is essential to turning Vector's technology platforms into lasting commercial value," said Tommy Thompson, Chairman of Vector Science and Therapeutics and former U.S. Secretary of Health and Human Services. "Angus's background in healthcare investment banking, law and pharmaceutical manufacturing gives the Company the expertise to evaluate and execute strategic opportunities with rigor, and we are pleased to welcome him to the team."

"Angus brings a rare combination of transaction experience and hands-on operating knowledge of pharmaceutical manufacturing, which is exactly what Vector needs as we scale," said Russell Starr, President of Vector Science and Therapeutics. "As we evaluate partnerships and acquisitions that complement our delivery technologies and peptide platform, his ability to identify, structure and execute the right opportunities will be an important asset to the Company and our shareholders."

"I am excited to join Vector at an important stage in the Company's development," said Angus Jackson, Managing Director of Corporate Development. "Vector has an opportunity to build on its existing technology platforms, deepen strategic partnerships, and pursue new avenues for commercial growth. I look forward to working with the team to execute a disciplined growth strategy that combines organic expansion with targeted strategic transactions and partnerships."

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing drug delivery technology and pharma-grade peptide manufacturing for the sports medicine, regenerative medicine, and pain management markets. Vector's peptides are pharma-grade, not research-grade: they are manufactured under cGMP, FDA, and ISO-compliant conditions, Rx-labeled, and sold directly to physicians for physician use, rather than distributed through the research-only channels associated with research-grade material. The Company's product and intellectual property portfolio is focused on advanced transdermal delivery, precision catheter systems, localized pain management, pancreatic oncology, and smart wound care. Vector is headquartered in Mequon, Wisconsin. For more information, visit https://vectorscience.co/.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding Mr. Jackson's anticipated role and responsibilities, the Company's growth strategy, and the Company's intention to pursue commercial expansion, strategic partnerships, business development initiatives, investments and acquisitions. Forward-looking information is based on management's current expectations and assumptions and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied, including the risk that the Company does not identify suitable partnerships, investments or acquisitions, that any such transactions are not completed on acceptable terms or at all, that required financing or regulatory and stock exchange approvals are not obtained, or that the anticipated benefits of any transaction are not realized. Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake any obligation to update forward-looking information except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Vector Sciences & Therapeutics

Share this article

PROPOSED SETTLEMENT OF DERIVATIVE AND CLASS ACTION, SETTLEMENT HEARING, AND RIGHT TO APPEAR ANNOUNCED IN ATLAS STOCKHOLDER CLASS ACTION LITIGATION

PHILADELPHIA, Oct. 19, 2026 /PRNewswire/ -- The following statement is being issued by Kroll Settlement Administration LLC regarding Ayers v. Brigham, Atlas Energy Solutions.

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE AND CLASS ACTION, SETTLEMENT HEARING, AND RIGHT TO APPEAR

TO: All (1) record holders and beneficial owners of Atlas Energy Solutions, Inc. ("Atlas" or the "Company") Class A common stock (NYSE: "AESI") as of October 2, 2023; and (2) Current Stockholders of Atlas common stock.1

PLEASE READ THIS SUMMARY NOTICE CAREFULLY. YOUR RIGHTS WILL BE AFFECTED BY A DERIVATIVE AND CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, pursuant to an Order of the Court of Chancery of the State of Delaware (the "Court"), that the above-captioned derivative and class action lawsuit (the "Action") is pending in the Court.

YOU ARE ALSO NOTIFIED that Patrick Ayers ("Plaintiff"), individually and on behalf of the Class and derivatively on behalf of Atlas, has reached a proposed settlement with defendants Ben M. Brigham, Douglas G. Rogers, A. Lance Langford, Stacy Hock, Stephen Cole, Atlas Sand Holdings, LLC, Atlas Sand Holdings II, LLC, Atlas Sand Management Company, LLC, and Atlas Sand Management Company II, LLC (collectively, "Defendants," and together with Plaintiff and Atlas, the "Parties") for $17,000,000 in cash (the "Settlement"). The terms of the Settlement are stated in the Stipulation and Agreement of Settlement, Compromise, and Release among the Parties, dated September 10, 2026 (the "Stipulation"), a copy of which is available at www.AtlasStockholderClassActionLitigation.com. If approved by the Court, the Settlement will resolve all claims in the Action against Defendants, and the Action will be dismissed with prejudice.

A hearing (the "Settlement Hearing") will be held on December 18, 2026, at 1:30 p.m. E.T., before The Honorable J. Travis Laster, Vice Chancellor, either in person at the Court of Chancery of the State of Delaware, New Castle County, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware 19801, or remotely by Zoom (in the discretion of the Court), to, among other things: (i) determine whether to certify the Settlement Class, appoint Plaintiff as Settlement Class representative, and appoint Plaintiff's Counsel as Settlement Class counsel (in each instance, for Settlement purposes); (ii) determine whether the Court should approve the proposed Settlement as fair, reasonable, and adequate to the Settlement Class and Atlas; (iii) determine whether a Judgment substantially in the form attached as Exhibit D to the Stipulation should be entered dismissing the Action with prejudice against Defendants and granting the Releases set forth in the Stipulation; (iv) determine whether the proposed plan of allocation of the Settlement Fund is fair and reasonable, and should therefore be approved; (v) determine whether the application by Plaintiff's Counsel for an award of attorneys' fees and litigation expenses ("Fee and Expense Award"), and any incentive award to Plaintiff to be paid solely from any Fee and Expense Award, should be approved; (vi) hear and determine any objections to the Settlement or Plaintiff's Counsel's application for an award of attorneys' fees and litigation expenses and any incentive award to Plaintiff; and (vii) consider any other matters that may properly be brought before the Court in connection with the Settlement. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the Settlement website, www.AtlasStockholderClassActionLitigation.com.

If you are a member of the Settlement Class or a Current Stockholder, your rights will be affected by the pending Action and the Settlement. If you are a member of the Settlement Class, you may be entitled to share in the Net Settlement Fund. If you have not yet received the full Notice, you may obtain a copy of the Notice by contacting the Notice Administrator at Atlas Stockholder Class Action Litigation, c/o Kroll Settlement Administration LLC, P.O. Box 225391, New York, NY 10150-5391. A copy of the Notice can also be downloaded from the Settlement website, www.AtlasStockholderClassActionLitigation.com.

If the Settlement is approved by the Court and the Effective Date occurs, the Net Settlement Fund will be distributed on a pro rata basis to "Settlement Class" members in accordance with the proposed Plan of Allocation stated in the Notice or such other plan of allocation as is approved by the Court. Under the proposed Plan of Allocation, all Settlement Class members who held or beneficially owned shares of Former Atlas Class A common stock as of the Closing on October 2, 2023, and whose shares of Former Atlas Class A common stock were exchanged for shares of New Atlas Class A common stock in the Reorganization (their "Eligible Shares") will be eligible to receive a pro rata payment from the Net Settlement Fund equal to the product of (i) the number of Eligible Shares held by the Settlement Class member and (ii) the "Per-Share Recovery" for the Settlement, which will be determined by dividing the total amount of the Net Settlement Fund by the total number of Eligible Shares. As explained in further detail in the Notice, pursuant to the Plan of Allocation, payments from the Net Settlement Fund to Settlement Class members will be made through the same accounts through which Settlement Class members received their shares of New Atlas Class A common stock in the Reorganization. Settlement Class members do not need to submit a claim form to receive a payment from the Settlement.

Settlement Class members and Current Stockholders have the right to object to the Settlement. Any objections to the proposed Settlement, the proposed Plan of Allocation, or Plaintiff's Counsel's application for the Fee and Expense Award and any incentive award to Plaintiff in connection with the Settlement must be filed with the Register in Chancery in the Court of Chancery of the State of Delaware and delivered to Plaintiff's Counsel and Defendants' counsel such that they are received no later than November 25, 2026, in accordance with the instructions set forth in the Notice.

Please do not contact the Court or the Office of the Register in Chancery regarding this notice. All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Notice Administrator or Plaintiff's Counsel.

Requests for the Notice should be made to the Notice Administrator:

Atlas Stockholder Class Action Litigation

c/o Kroll Settlement Administration LLC

P.O. Box 225391

New York, NY 10150-5391

Inquiries, other than requests for the Notice, should be made to Plaintiff's Counsel:

Kimberly Evans

BLOCK & LEVITON LLP

222 Delaware Avenue, Suite 1120

Wilmington, DE 19801

[email protected]

Mark Richardson

LABATON KELLER SUCHAROW LLP

222 Delaware Avenue, Suite 1510

Wilmington, DE 19801

[email protected]

Jeremy Friedman

FRIEDMAN & TEJTEL PLLC

493 Bedford Center Road, Suite 2D

Bedford Hills, NY 10507

[email protected]

Dated: October 6, 2026

BY ORDER OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE

1 Any capitalized terms used in this Summary Notice that are not otherwise defined in this Summary Notice shall have the meanings given to them in the full Notice of Proposed Settlement of Derivative and Class Action, Settlement Hearing, and Right to Appear (the "Notice"), available at www.AtlasStockholderClassActionLitigation.com.

SOURCE Kroll Settlement Administration LLC

Share this article

- Positive Phase 1 data were previously presented in an oral session at ASCO 2026

- Emi-Le received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the proposed treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation

BOSTON, Oct. 19, 2026 /PRNewswire/ -- Servier today announced the first patients have been dosed in the pivotal Phase 2 cohort (EMBLEM-1) of a Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in solid tumors. EMBLEM-1 is evaluating the antitumor activity and safety of Emi-Le, an investigational antibody drug conjugate (ADC) directed against B7-H4, in aggressive adenoid cystic carcinoma (ACC).

"Dosing these first patients marks an important step in advancing Emi-Le as a potential targeted treatment for ACC, a difficult-to-treat cancer with no FDA-approved systemic treatment options," said Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals. "This milestone also underscores the momentum of Servier's growing oncology portfolio and our commitment to bringing scientific rigor and meaningful innovation to rare cancers where patients face significant unmet need. We look forward to sharing these data with the scientific community."

The primary endpoint is objective response rate (ORR)—defined as the percentage of patients who achieve a best overall response of confirmed complete response (CR) or partial response (PR)— per RECIST 1.1.

The initiation of EMBLEM-1 is supported by clinical data from a Phase 1 analysis of Emi-Le, which demonstrated a differentiated safety profile and were presented in an oral session at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.

Earlier this year, Emi-Le received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the proposed treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation.

The EMBLEM-1 cohort is currently enrolling (NCT05377996). Additional details regarding the clinical trial can be found here.

Media contact 

Darby Malkin: [email protected] 

About Emi-Le

Emi-Le is an investigational B7-H4-directed Dolasynthen antibody drug conjugate (ADC) with a drug-to-antibody ratio (DAR) of 6 and a proprietary auristatin-F HPA payload designed to provide a controlled bystander effect as demonstrated in preclinical models. Emi-Le is under evaluation in an ongoing Phase 1/2 clinical trial and has not been approved by the FDA, and its safety and effectiveness have not been established. The U.S. Food and Drug Administration has granted Fast Track designations to Emi-Le for the treatment of 1) adult patients with advanced or metastatic triple-negative breast cancer, and 2) advanced or metastatic HER2 low / HER2 negative breast cancer post-topo-1 ADC (including TNBC and certain HR+ breast cancers). It has also received Breakthrough Designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma with solid histology or high-grade transformation. For more information about the trial, visit clinicaltrials.gov (NCT05377996).

About Adenoid Cystic Carcinoma

Adenoid cystic carcinoma (ACC) occurs in the secretory glands, typically in the head and neck, but also in other areas of the body. Globally, more than 200,000 people have ACC. It is diagnosed in roughly four per one million people annually and does not discriminate by ethnicity or lifestyle factors. Today there are no approved or preferred systemic therapies to treat advanced or metastatic ACC; most people are treated with surgery or radiation, but the disease recurs in 50 percent of cases, often becoming more aggressive with metastases in distant areas of the body.1

About Servier in Oncology

Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities. 

Servier invests close to 20% of revenue from brand-name medicines in R&D each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time.

Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio.

For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.com and Servier.us.

Disclosures

This release contains general information about the Servier Group and its entities (hereinafter "Servier and its Affiliates") and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect.

Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks.

This statement also contains forward-looking statements that are subject to varying levels of uncertainty and risk. Investigational new drugs and indications are subject to further scientific and medical review and regulatory approval. They are not approved for use by the FDA.

Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction.

The content of this document is a summary only, is not complete, and does not include all material information about Servier and its Affiliates, including potential conflicts of interest.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor does it accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document is accurate or complete.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same. The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice.

References

1 Adenoid Cystic Carcinoma Research Foundation. Accessed May 2026.

SOURCE Servier Pharmaceuticals

Share this article

- Students across the U.S. can apply for $3,000 scholarships for eligible technical education and training programs

- Schneider Electric's additional $100,000 investment supports training for careers in buildings, energy and critical infrastructure

ATLANTA, Oct. 19, 2026 /PRNewswire/ -- Schneider Electric, a global energy technology leader, and SKILLED Nation, an organization that expands access to education and training for high-demand skilled careers, are inviting students across the United States to apply for $3,000 scholarships through the Schneider Electric SKILLED Scholarship Program.

As investment in electrification, building modernization and critical infrastructure accelerates across the U.S., developing the skilled workforce needed to support these industries has become an increasingly important priority for America's energy future. To help address this challenge, Schneider Electric and SKILLED Nation are announcing an additional $100,000 in scholarships for technical education and training nationwide.

Now in its fourth year, the Schneider Electric SKILLED Scholarship Program has received more than $300,000 in funding from Schneider Electric to help students pursue technical careers across America's buildings, energy systems and critical infrastructure. The scholarships help fund postsecondary education and training that can lead to careers in building automation, energy management, HVAC, electrical systems, facilities engineering and maintenance, green building and sustainability, security and related technical fields.

"For us, the real measure of this program is where it can take students," said Alvin Townley, Founding Executive Director of SKILLED Nation. "These scholarships help students pay for the training to gain practical skills for careers installing, operating and maintaining the systems that power our buildings, energy infrastructure and communities."

Developing Technical Talent for Energy and Infrastructure

As buildings and energy infrastructure become more electrified, connected and intelligent, developing specialized technical skills is essential to helping customers realize the full value of modernization.

"The future of American energy infrastructure will be defined as much by the talent behind it as the technology powering it," said Chris Collins, Senior Vice President, Secure Power, North America, Schneider Electric. "At Schneider Electric, we see workforce development as a strategic investment in our customers' competitiveness, our nation's energy resilience and the next generation of American industry. Our partnership with SKILLED Nation helps students access the technical education and training to build that future."

Building on 190 years of innovation globally and more than 135 years of operations in the U.S., Schneider Electric is investing in the technology and talent essential to modernizing energy infrastructure. Since 2009, Schneider Electric has trained more than 1 million young people across more than 60 countries, helping them build practical skills in energy management. Through its Impact 2030 sustainability ambition, the company aims to equip more than 3 million young people with skills in electrification and sustainability. The SKILLED Nation partnership extends that global commitment in the U.S., creating pathways to technical careers that will help shape the future of American industry.

Launched in 2022 with scholarships in New York and New Jersey, Schneider Electric's partnership with SKILLED Nation later expanded to Boston, Dallas and other communities. The scholarships are open to qualifying students nationwide.

How to Apply for a Scholarship

The deadline to apply is Tuesday, Nov. 10. To apply, visit https://skilled-nation.org/partner/sescholarship.

Schneider Electric employees, their spouses and their dependents are not eligible to apply.

About SKILLED Nation

SKILLED Nation partners with corporations, foundations and philanthropic leaders to expand access to education and training for high-demand skilled careers. Through scholarship programs and workforce partnerships, SKILLED Nation helps individuals pursue skills and credentials that increase economic mobility while helping employers build the skilled workforce they need.

Learn more at www.skilled-nation.org.

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability. The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world's most sustainable companies. 

SOURCE Schneider Electric

Share this article

Hypershell Named to TIME's 2026 Best Inventions

Redefining the boundaries of human performance, the Hypershell X Ultra S earns top recognition from TIME

- TIME Best Inventions 2026: Hypershell X Ultra S has been named to TIME's Best Inventions of 2026 in the Sports & Fitness category, recognizing its groundbreaking innovation and contribution to advancing the future of human mobility.

- A Year of Industry Recognition: The TIME recognition builds on a standout year for Hypershell, with its AI-powered consumer exoskeletons earning accolades from leading publications including Fast Company and Tom's Guide, among others.

- Redefining Human Performance: At the forefront of wearable mobility innovation, Hypershell's award-winning X Series combines a lightweight, foldable 1.7 kg design with technologies engineered to reduce physical exertion. The series is the world's first consumer exoskeleton lineup to have its performance verified by both TÜV Rheinland and SGS.

HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Hypershell, the world's leading consumer exoskeleton brand, is excited to announce that X Ultra S has been selected for TIME's 2026 Best Inventions list in the Sports & Fitness category. The recognition underscores Hypershell's continued innovation in AI-powered wearable robotics and its mission to expand human mobility through technology.

For 26 years, TIME has highlighted the world's most impactful new products and ideas through its annual Best Inventions issue. Each year, innovations across rapidly evolving fields are evaluated against key criteria such as originality, efficacy, ambition, and real-world impact.

"It's an incredible honor to have Hypershell X Ultra S recognized among TIME's Best Inventions of 2026. Exoskeletons are no longer science fiction. They're helping everyday people go farther than they thought possible," said Kelvin Sun, founder and CEO of Hypershell.

Highlighting the growing demand in a global exoskeleton market projected to reach $1.79 billion by 2033, TIME commended Hypershell X Ultra S for overcoming a common industry hurdle: the rigid feel of traditional robotic wearables. X Ultra S addresses this with its groundbreaking HyperIntuition™ motion control algorithm, which analyzes and anticipates a user's movements in real time to allow for remarkably fluid motion.

"X Ultra S brings AI and precision robotics together with advanced wearable technology to take the strain off your legs and knees, lighten every climb, and help you go farther with less fatigue," Kelvin added. "Powered by HyperIntuition™, X Ultra S delivers intuitive, seamless assistance that moves naturally with the wearer, making it feel more like an extension of the body than a rigid external device."

Key features of the Hypershell X Ultra S include:

- The flagship model X Ultra S is built for mixed terrain and demanding outdoor conditions. The revolutionary HyperIntuition™ motion control algorithm analyzes user movements in real-time for seamless, natural assistance without the rigidity of traditional exoskeletons.

- The ultra-lightweight, 1.7 kg foldable device is verified by Germany's TÜV Rheinland to achieve 97.5% gait synchronization.

- Powered by a 1000W motor system that responds to the user's stride in just 0.31 seconds, SGS certification proves the exoskeleton decreases average oxygen consumption by up to 39.2% and lowers average heart rate by up to 42.7%.

- Built with an aerospace-grade titanium alloy chassis to withstand the elements from -20°C to 60°C, the exoskeleton offers adventurers hands-free control via the Hypershell+ app and Apple Watch to effortlessly amplify their natural exploration.

The TIME recognition further adds to a remarkable year for Hypershell, following honors from Fast Company's 2026 Next Big Things in Tech, Fast Company's World Changing Ideas Awards and the Tom's Guide Fitness Awards 2026. Together, these recognitions reflect growing industry acknowledgment of Hypershell's role in bringing consumer exoskeleton technology closer to mainstream adoption.

The full Hypershell X Series lineup is available now at Hypershell.com and on Amazon.

All product specifications are subject to the information published on the official Hypershell website.

About Hypershell

Founded in 2021, Hypershell is a world-leading exoskeleton company focused on empowering human exploration. Its intelligent exoskeletons adapt in real time to terrain, activity, and intention, making movement lighter and more natural. With SGS-certified and TÜV Rheinland-verified performance and tens of thousands of units sold across 70+ countries, Hypershell enhances, not replaces, human ability – shaping a future where wearable robotics become as essential as backpacks for exploration, work, and play.

SOURCE Hypershell

Share this article

Calamos Extends Autocallable Leadership through CAYN--World's First Indexed Least-Of Autocallable Income ETF

- Calamos continues to innovate in autocallable ETFs with an indexed approach to the popular "least-of" (also known as "worst-of") autocallable income structure—expanding upon the broadest line of autocallable ETFs in the world.

- CAYN links income payments and principal repayment to the weakest performer among SPY, QQQ and IWM, via a weekly ladder of synthetic notes, each with a three-year maturity, 30% downside coupon and principal barriers, and a coupon-memory feature.

- CAYN seeks enhanced tax efficiency, improved coupon reliability and greater principal preservation relative to single notes and non-indexed worst-of ETFs.

METRO CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ -- John Koudounis, President and CEO of Calamos, a leading alternatives manager, today announced the planned launch of the Calamos Least-Of Autocallable Income ETF (CAYN) on October 26, 2026. Calamos developed CAYN with MerQube and Citibank as the world's first indexed approach to autocallable income tied to the popular "worst-of" structured note strategy.

"The autocallable ETF category is taking off, with growing investor demand for multiple strategies. Our planned launch of CAYN further demonstrates Calamos' leadership in the autocallable ETF space that we created with CAIE in 2025," said John Koudounis, President and CEO of Calamos. "We're excited to improve the least-of strategy and to soon offer another powerful product for income-oriented investors seeking higher coupons from equities."

Calamos was named Asset Manager of the Year (AUM between $25 billion and $500 billion) at the 2026 MMI/Barron's Industry Awards. Its Autocallable ETF lineup has also received multiple awards alone in 2026, including Investment Product Innovation (MMI/Barron's) and, from SRP Americas, Best Structured ETF Solution and ETF Innovation of the Year.1

"For investors looking for a worst-of autocallable solution, we've built the first indexed least-of autocallable strategy, designed to bring tax-efficiency, liquidity, and a degree of principal preservation and coupon reliability to the most popular product type in the legacy autocallable yield note market," said Matt Kaufman, Global Head of ETFs at Calamos. "CAYN will use the same 'Structured ETF' framework that has powered the success of CAIE, CAIQ and CAGE—trading an index on swap, an innovation that the worst-of autocallable strategy has never seen before in the ETF space. We look forward to expanding the Calamos Autocallable ETF family for investors seeking one of the most popular forms of autocallable income via the ETF wrapper."

About the ETF

CAYN is designed to seek high, tax-efficient income by tying income and principal repayment to the weakest performer among three ETFs representing large-cap stocks (SPY), growth stocks (QQQ) and small-cap stocks (IWM). Rather than investing in a single worst-of autocallable note ("note") or a non-indexed worst-of autocallable ETF, CAYN provides exposure to a weekly laddered index of at least 52 synthetic worst-of autocallable notes, each with a three-year maturity and 30% downside coupon and principal barriers. When a note in the portfolio is called away, the principal is returned to the fund and reinvested in a new note with the same terms. Each note's three-year term is designed to allow more time to recover from market declines, seeking to reduce the risk of principal impairment.

CAYN's index also features a "memory" mechanism that stores missed coupons and pays them once the worst-performing constituent is back above the coupon barrier. Calamos will trade the MerQube US Equity Least-Of Autocallable Index (MQAUTOWL) on swap. CAYN intends to take a multi-counterparty approach, with Citibank as the primary counterparty.

To learn more, see the filing on SEC EDGAR here, and visit Autocallable ETFs | Calamos Investments

About Calamos

Calamos is a diversified global investment firm, headquartered in the Chicago metropolitan area, offering innovative investment strategies, including autocallables, Bitcoin, liquid alternatives, convertible, equity, fixed income, multi-asset, hedge fund, private credit, and private equity. With more than $53 billion in AUM, including more than $26 billion in liquid alternatives assets as of September 30, 2026, the firm offers strategies through ETFs, mutual funds, closed-end funds, interval funds, UCITS funds and separately managed portfolios. Clients include financial advisors, wealth management platforms, pension funds, foundations & endowments, and individuals, globally. For more information, visit us on LinkedIn, X (formerly Twitter), Instagram (@calamos_investments), or at www.calamos.com

Before investing, carefully consider the Fund's investment objectives, risks, charges and expenses. Please see the prospectus and summary prospectus containing this and other information which can be obtained by calling 1-866-363-9219. Read it carefully before investing.

An investment in the Fund is subject to risks, and you could lose money on your investment in the Fund. There can be no assurance that the Fund will achieve its investment objective. Your investment in the Fund is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation (FDIC) or any other government agency. The risks associated with an investment in the Fund can increase during times of significant market volatility. The Fund also has specific principal risks, which are described below. More detailed information regarding these risks can be found in the Fund's prospectus. The principal risks of investing in the Calamos Least-of Autocallable Income Fund include: authorized participant concentration risk, autocallable structure risk, contingent income risk, early redemption risk, barrier risk, box spread risk, calculation methodology risk, cash holdings risk, correlation risk, costs of buying and selling fund shares, counterparty risk, credit risk, derivatives risk, equity securities risk, FLEX options risk, index risk, interest rate risk, investment in a subsidiary, laddered portfolio risk, liquidity risk, market maker risk, market risk, new fund risk, non-diversification risk, other investment companies risk, premium-discount risk, secondary market trading risk, swap arrangement risk, swap agreement termination risk, tax risk, trading issues risk, valuation risk.

Autocallable Structure Risk — The Fund's returns are correlated to the performance of a theoretical portfolio of Autocallables reflected by the Autocallable Index. Autocallable notes have specific structural features that may be unfamiliar to many investors.

Contingent Income Risk — Coupon payments from the Autocallables are not guaranteed and will not be made if the least performing Constituent falls below the Coupon Barrier on Observation Dates. This means the Fund may generate significantly less income than anticipated during market downturns.

Barrier Risk — If the least-performing Constituent falls below the Maturity Barrier at the maturity of an Autocallable in the Index Portfolio, that portion of the Index Portfolio will be fully exposed to the negative performance of the least-performing Constituent from its initial level. This conditional protection creates a binary outcome that can result in sudden, significant losses if barriers are breached.

Citibank N.A. acts as the Primary Swap Provider and Citigroup Global Markets Inc. (together, "Citi") acts as the Authorized Participant with respect to CAYN. Citi has not participated in the preparation of this presentation and makes no representation or warranty, express or implied, regarding the accuracy or completeness of any information contained herein. Citi does not sponsor, endorse, sell or promote CAYN and makes no representation or warranty, express or implied, regarding the advisability of investing in securities generally or in CAYN particularly. Citi has no obligation to take the needs of CAYN or its investors into consideration in acting as the primary swap provider for CAYN, may engage in trading and hedging activities (including in the reference assets) for its own account that could affect the value of CAYN, and shall have no liability in connection with the administration, marketing or trading of CAYN.

1Selection criteria and methodologies for awards: Impact Awards | Money Management Institute, Home - SRP Americas Awards 2026

SOURCE Calamos Investments

Share this article

BEVERLY, Mass., Oct. 19, 2026 /PRNewswire/ -- DataOne Software, a Dominion Enterprises company and a leading provider of automotive data and software solutions, today announced the availability of Massachusetts vehicle registration and sales data within its Cross-Sell Reports market intelligence solutions for dealers. Cross-Sell Reports, including the Cross-Sell Interactive web interface, provide auto dealers with unparalleled insight into local market trends, giving them a competitive edge in reaching new customers and expanding market share. The addition of Massachusetts data to Cross-Sell Reports expands coverage to 40 states.

"As of today, Massachusetts dealers can now access a current, accurate view of new and used vehicle transactions within their market area," explains David Wall, DataOne head of Cross-Sell Reports. "Localized data, in easy-to-interpret views, are an incredible advantage to dealers who want to spot trends early and make decisions based on accurate market intelligence. We are thrilled to be bringing this capability not only to Massachusetts dealers but also to dealerships in other New England states whose target markets cross into Massachusetts."

On average, over 3.8 million vehicle transactions are processed monthly for inclusion in Cross-Sell Reports, covering new and used dealer transactions across 40 states, all sourced from official state DMV records. Each dealer subscription is configured to the dealer's unique market area and provides:

- Competitive market share analysis by dealership, make, and model

- ZIP code-level heat mapping to identify buyer activity and emerging markets

- Inventory trend analysis to inform stocking decisions by segment and season

- Interactive dashboards with drill-down reporting — no analytics infrastructure required

"We know dealers trust Cross-Sell Reports for critical market insight, and for those insights to be delivered with industry-leading speed and timeliness," says Jake Maki, DataOne President. "With the addition of Massachusetts state coverage, we continue to expand our coverage providing more dealers with the most immediate, accurate market intelligence available."

Since welcoming the Cross-Sell brand into DataOne earlier this year, DataOne has accelerated efforts to expand state coverage of vehicle registration and sales data. In addition to Massachusetts, Cross-Sell Reports recently added Mississippi, Kansas and Georgia to its coverage.

"Our goal is to make DataOne the most accurate and comprehensive source of vehicle registration and sales data, however customers choose to use it," says Maki. "For a dealer, that might be a Cross-Sell Interactive dashboard tuned to their local market. For other customers looking to license the data, it might be multi-state data integrated directly into their own platforms. Every new state we add makes both more valuable."

In addition to Cross-Sell Reports and Cross-Sell Interactive, DataOne offers Vehicle Registration and Sales Data for licensing via API or FTP data feed, with coverage configurable by state or region.

For general information about DataOne solutions, contact DataOne at 877.438.8467, e-mail [email protected] or visit dataonesoftware.com. For specific information about Cross-Sell Reports or Cross-Sell Interactive for dealers, visit Cross-Sell Reports.

About DataOne Software

DataOne Software (www.dataonesoftware.com) is a premier automotive data source providing the data and software solutions needed to power modern businesses across all segments of the automotive industry. DataOne's comprehensive data solutions cover everything from VIN decoding and vehicle descriptions to specifications, optional equipment, and market pricing. With the acquisition of Cross-Sell in 2026, DataOne has expanded our product offering to include PII-free vehicle sales and registration data. Our high-quality solutions are delivered with industry-leading support, making them easy to integrate and scale.

Media Contact

Alice Fackre, Product and Brand Marketing Manager

Email: alice[email protected]

Phone: (978) 473-9097

SOURCE DataOne Software

Share this article